Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

McGregor CG., Adams A., Sadler R., Arancibia-Cárcamo CV., Palmer R., Ambrose T., Brain O., Walsh A., Klenerman P., Travis SP., Croft NM., Lindsay JO., Satsangi J.

DOI

10.1136/gutjnl-2021-324116

Type

Journal article

Journal

Gut

Publication Date

12/2021

Volume

70

Pages

2398 - 2400

Addresses

Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK colleen.mcgregor@ndm.ox.ac.uk.

Keywords

Humans, Inflammatory Bowel Diseases, Pandemics, Antibodies, Monoclonal, Humanized, Infliximab, United Kingdom, COVID-19, SARS-CoV-2

Permalink Original publication